A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies
A Study of DCC-2618 in Patients with Advanced Malignancies
Sponsor: Deciphera Pharmaceuticals, LLC
Enrolling: Male and Female Patients
IRB Number: AAAR7574
U.S. Govt. ID: NCT02571036
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study will test an investigational study drug called DCC-2618. This research study will explore the following: find the highest safe dose of DCC-2618, see how often DCC-2618 should be given, see how well research participants with cancer tolerate DCC-2618, and evaluate if DCC-2618 is effective against cancer. Cancers include: brain tumors, spinal tumors, leukemia
This study is closed
Investigator
Mark Heaney, MD, PhD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a confirmed solid tumor or blood cancer? Yes No
Are you willing to undergo biopsies while on study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE